On February 23, 2023, the European Medicines Agency (EMA) published a positive opinion for the use of the molecule “Ruxolitinib” in Europe. This is marketed by Incyte Biosciences Laboratory in the form of a cream for the treatment of non-segmental vitiligo for adults and adolescents over 12 years of age.

Ruxolitinib

In the Netherlands, according to the usual marketing and reimbursement procedures for a medicine, the authorization process can start in the coming months.

We will publish more information about this treatment and the next steps regarding admission in the Netherlands on this website in due course.